BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...v6 of CD44 (CD44v6) B7-H3 (CD276) AXL receptor tyrosine kinase (AXL) (UFO) Carcinoembryonic antigen (CEA) Claudin 18 (CLDN18) Claudin 6 (CLDN6) Delta like canonical Notch ligand 3 (DLL3) Epidermal...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...Co. Ltd. Zhejiang University c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Delta like canonical Notch ligand 3 (DLL3) Epidermal...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

...CD33 (SIGLEC3) Acute myelogenous leukemia (AML) Mkt DNA crosslinkers AbbVie Inc. (NASDAQ:ABBV) Rovalpituzumab tesirine Cleavable Delta like canonical Notch ligand 3 (DLL3)...
BioCentury | Jan 11, 2019
Company News

AbbVie records $4B impairment on Stemcentrx deal

...assets for further impairment. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer Chris Lieu Rova-T, rovalpituzumab tesirine (SC16LD6.5) AbbVie Inc. Delta like canonical Notch ligand 3 (DLL3) Small...
BioCentury | Jan 6, 2019
Company News

AbbVie records $4B impairment on Stemcentrx deal

...monitor the remaining $1 billion of Stemcentrx assets for further impairment. Chris Lieu Rova-T, rovalpituzumab tesirine (SC16LD6.5) AbbVie Inc. Delta like canonical Notch ligand 3 (DLL3) Small...
BioCentury | Jan 4, 2019
Financial News

On heels of series C, Harpoon files for IPO

...PacGrow are underwriting the IPO. Harpoon Therapeutics Inc., South San Francisco, Calif. Elizabeth S. Eaton HPN424 HPN536 Harpoon Therapeutics Inc. Delta like canonical Notch ligand 3 (DLL3) Prostate-specific...
BioCentury | Dec 27, 2018
Financial News

On heels of series C, Harpoon files for IPO

...2015. Citigroup, Leerink, Canaccord Genuity and Wedbush PacGrow are underwriting the IPO. Elizabeth S. Eaton HPN424 HPN536 CD3 Harpoon Therapeutics Inc. Delta like canonical Notch ligand 3 (DLL3) Mesothelin Prostate-specific...
BioCentury | Dec 21, 2018
Financial News

ABL Bio raises $80M in Korean IPO

ABL Bio Inc. (KOSDAQ:298380) raised W90 billion ($80 million) through the sale of 6 million shares at W15,000 in an IPO in South Korea. The offering values the company at W668.8 billion ($594.4 million). In...
BioCentury | Dec 7, 2018
Clinical News

AbbVie's Rova-T suffers another setback in SCLC

...The open-label, international TAHOE trial was slated to enroll about 600 SCLC patients with high delta like canonical Notch ligand 3 (DLL3)...
...Population" ). AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Rova-T rovalpituzumab tesirine Business: Cancer Molecular target: Delta like canonical Notch ligand 3 (DLL3)...
...clinical benefit rate (CBR) Status: Phase III data Milestone: NA Brian Moy Rova-T, rovalpituzumab tesirine (SC16LD6.5) AbbVie Inc. Stemcentrx Inc. Delta like canonical Notch ligand 3 (DLL3)...
BioCentury | Dec 5, 2018
Clinical News

AbbVie's Rova-T suffers another setback in SCLC

...The open-label, international TAHOE trial was slated to enroll about 600 SCLC patients with high delta like canonical Notch ligand 3 (DLL3)...
...setting (see "Opdivo Gets Accelerated Approval in SCLC Population" ). Brian Moy Rova-T, rovalpituzumab tesirine (SC16LD6.5) AbbVie Inc. Stemcentrx Inc. Delta like canonical Notch ligand 3 (DLL3)...
Items per page:
1 - 10 of 21